Mary Wilson
Well-known member
Published: 01 March 2023
https://doi.org/10.1093/infdis/jiad052
Matthijs P Raadsen, Christine Dahlke, Anahita Fathi, Mart M Lamers, Petra van den Doel, Luca M Zaeck, Martin E van Royen, Erwin de Bruin, Reina Sikkema, Marion Koopmans,
Eric CM van Gorp, Gerd Sutter, Rory D de Vries, Marylyn M Addo, Bart L Haagmans
Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus (MPXV) and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome- associated coronavirus (MERS-CoV). Here, we report that cross-reactive MPXV nAbs were detectable in only a single subject after the first dose, 3 out of 10 after the 2nd dose, and in 10 out of 10 after the 3rd dose of MVA-MERS-S vaccine.
https://watermark.silverchair.com/j...8UO2qNPqHisnPvVOeLPrjDLIJ3SKVKoEWMmBZHYVwQXiJ
https://doi.org/10.1093/infdis/jiad052
Matthijs P Raadsen, Christine Dahlke, Anahita Fathi, Mart M Lamers, Petra van den Doel, Luca M Zaeck, Martin E van Royen, Erwin de Bruin, Reina Sikkema, Marion Koopmans,
Eric CM van Gorp, Gerd Sutter, Rory D de Vries, Marylyn M Addo, Bart L Haagmans
Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus (MPXV) and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome- associated coronavirus (MERS-CoV). Here, we report that cross-reactive MPXV nAbs were detectable in only a single subject after the first dose, 3 out of 10 after the 2nd dose, and in 10 out of 10 after the 3rd dose of MVA-MERS-S vaccine.
https://watermark.silverchair.com/j...8UO2qNPqHisnPvVOeLPrjDLIJ3SKVKoEWMmBZHYVwQXiJ